Hidenori Toyoda Selected Research

Fatigue

1/2023	Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
1/2023	Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
1/2023	Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
3/2022	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
1/2022	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hidenori Toyoda Research Topics

Disease

198	Hepatocellular Carcinoma (Hepatoma) 05/2024 - 03/2002
77	Infections 12/2023 - 11/2002
62	Chronic Hepatitis C 02/2024 - 03/2002
52	Neoplasms (Cancer) 01/2024 - 11/2005
50	Fibrosis (Cirrhosis) 05/2024 - 01/2006
27	Chronic Hepatitis B 04/2024 - 07/2006
25	Liver Cirrhosis (Hepatic Cirrhosis) 05/2024 - 02/2004
23	Liver Diseases (Liver Disease) 12/2023 - 04/2011
18	Liver Neoplasms (Liver Cancer) 05/2024 - 08/2005
15	Hepatitis B 04/2024 - 01/2007
14	Hepatitis C 10/2023 - 04/2008
13	Non-alcoholic Fatty Liver Disease 03/2024 - 02/2013
10	Inflammation (Inflammations) 04/2024 - 02/2004
9	Hemorrhage 04/2024 - 04/2008
9	Neoplasm Metastasis (Metastasis) 12/2023 - 05/2004
6	Fatty Liver 10/2023 - 02/2013
6	Hypertension (High Blood Pressure) 10/2023 - 01/2022
6	Hepatitis 01/2022 - 07/2006
6	Chronic Hepatitis (Chronic Active Hepatitis) 12/2020 - 04/2007
5	Chronic Renal Insufficiency 10/2023 - 01/2018
5	Fatigue 01/2023 - 01/2022
5	Virus Diseases (Viral Diseases) 01/2023 - 12/2009
5	Carcinogenesis 12/2020 - 03/2002
4	Alcoholic Fatty Liver 01/2023 - 01/2012
4	Disease Progression 01/2022 - 03/2015
4	Anemia 05/2019 - 02/2014
4	Hemophilia A (Haemophilia) 03/2012 - 06/2004
3	Thrombosis (Thrombus) 08/2023 - 02/2021
3	Diabetes Mellitus 10/2022 - 01/2020
3	Ascites 05/2022 - 12/2012
3	Viremia 01/2021 - 01/2007
3	Persistent Infection 12/2020 - 01/2014

Drug/Important Bio-Agent (IBA)

64	Antiviral Agents (Antivirals)IBA 05/2024 - 11/2007
43	lenvatinibIBA 04/2024 - 01/2019
40	atezolizumabIBA 05/2024 - 01/2022
40	Bevacizumab (Avastin)FDA Link 05/2024 - 01/2022
38	InterferonsIBA 01/2023 - 03/2002
37	AlbuminsIBA 05/2024 - 01/2016
32	BilirubinIBA 05/2024 - 03/2009
28	Ribavirin (Virazole)FDA LinkGeneric 10/2023 - 03/2005
23	Biomarkers (Surrogate Marker)IBA 03/2024 - 12/2006
20	alpha-Fetoproteins (alpha-Fetoprotein)IBA 11/2023 - 08/2005
15	Tumor Biomarkers (Tumor Markers)IBA 08/2023 - 01/2006
15	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2011
15	Hepatitis B Surface Antigens (HBsAg)FDA Link 12/2022 - 01/2007
14	Fetal Proteins (Fetoprotein)IBA 05/2024 - 09/2007
13	Alanine Transaminase (SGPT)IBA 04/2024 - 03/2002
13	lentil lectinIBA 03/2024 - 08/2005
12	RNA (Ribonucleic Acid)IBA 12/2020 - 03/2002
11	AntigensIBA 04/2024 - 01/2016
11	acarboxyprothrombin (PIVKA)IBA 03/2024 - 09/2007
10	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 06/2004
9	MicroRNAs (MicroRNA)IBA 12/2020 - 05/2010
8	entecavir FDA Link 03/2024 - 07/2018
8	Pentetic Acid (DTPA)FDA LinkGeneric 07/2022 - 07/2011
8	GadoliniumIBA 07/2022 - 07/2011
8	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2017 - 06/2007
7	Sorafenib (BAY 43-9006)FDA Link 01/2023 - 04/2013
7	SofosbuvirIBA 03/2022 - 11/2014
7	gadolinium ethoxybenzyl DTPA FDA Link 01/2021 - 07/2011
6	tenofovir alafenamideIBA 04/2024 - 01/2021
6	Serum AlbuminIBA 10/2023 - 03/2015
6	Indicators and Reagents (Reagents)IBA 01/2023 - 09/2015
6	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2022 - 01/2015
6	glecaprevir and pibrentasvirIBA 05/2020 - 01/2018
5	Tenofovir (Viread)FDA Link 03/2024 - 07/2018
5	NucleotidesIBA 10/2023 - 01/2008
5	Immune Checkpoint InhibitorsIBA 06/2023 - 06/2020
5	Branched-Chain Amino AcidsIBA 01/2020 - 03/2014
5	asunaprevirIBA 08/2019 - 07/2016
5	daclatasvirIBA 08/2019 - 07/2016
5	Ritonavir (Norvir)FDA Link 04/2019 - 10/2015
5	ombitasvirIBA 04/2019 - 10/2015
5	paritaprevirIBA 04/2019 - 10/2015
4	Protons (Proton)IBA 12/2023 - 01/2019
4	EnzymesIBA 12/2023 - 01/2008
4	C-Reactive ProteinIBA 01/2023 - 01/2022
4	Transaminases (Aminotransferases)IBA 02/2022 - 01/2015
4	Hepatitis B e AntigensIBA 01/2022 - 11/2018
4	Hyaluronic Acid (Hyaluronan)IBA 01/2021 - 12/2012
4	Tyrosine (L-Tyrosine)FDA Link 01/2020 - 09/2015
4	telaprevirIBA 04/2015 - 01/2014
3	NucleosidesIBA 04/2024 - 03/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2023 - 01/2022
3	Protease Inhibitors (Protease Inhibitor)IBA 10/2023 - 01/2017
3	Small Heat-Shock ProteinsIBA 12/2022 - 01/2016
3	velpatasvirIBA 03/2022 - 07/2018
3	Keratin-18 (Keratin 18)IBA 11/2021 - 01/2017
3	ledipasvirIBA 03/2021 - 06/2015
3	pibrentasvirIBA 08/2020 - 01/2018
3	glecaprevirIBA 08/2020 - 01/2018
3	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2019

Therapy/Procedure

116	Therapeutics 05/2024 - 03/2002
6	Liver Transplantation 04/2023 - 01/2014
5	Aftercare (After-Treatment) 01/2022 - 12/2012
5	Renal Dialysis (Hemodialysis) 02/2019 - 07/2016
5	Hepatectomy 01/2016 - 08/2008
4	Duration of Therapy 08/2020 - 01/2009
4	Drug Therapy (Chemotherapy) 01/2020 - 05/2004
4	Radiofrequency Ablation 02/2018 - 12/2012